PFIZER INC Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net
PFIZER INC (PFE) reported Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net of $0 for the 3-month period ending 2017-10-01, per its 10-Q filed 2017-11-09.
Discontinued › Income Statement › Other Income
us-gaap:GainLossOnCashFlowHedgeIneffectivenessNet · last filed 2017-11-09
- PFIZER INC gain (loss) on cash flow hedge ineffectiveness, net for the quarter ending 2017-10-01 was $0.00.
- PFIZER INC gain (loss) on cash flow hedge ineffectiveness, net for the quarter ending 2017-07-02 was $0.00.
- PFIZER INC gain (loss) on cash flow hedge ineffectiveness, net for the quarter ending 2016-10-02 was $0.00.
- PFIZER INC gain (loss) on cash flow hedge ineffectiveness, net for the quarter ending 2016-07-03 was $0.00.
| Period end | Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net 3 month | Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net 6 month | Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net 9 month |
|---|---|---|---|
| 2017-10-01 | $0.00 10-Q · filed 2017-11-09 | $0.00 derived: sum of 2 quarters · filed 2017-11-09 | $0.00 10-Q · filed 2017-11-09 |
| 2017-07-02 | $0.00 10-Q · filed 2017-08-10 | $0.00 10-Q · filed 2017-08-10 | |
| 2016-10-02 | $0.00 10-Q · filed 2017-11-09 | $0.00 derived: sum of 2 quarters · filed 2017-11-09 | $0.00 10-Q · filed 2017-11-09 |
| 2016-07-03 | $0.00 10-Q · filed 2017-08-10 | $0.00 10-Q · filed 2017-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |